top of page

OUR DRUG PIPELINE

Promising disease product candidates for difficult to treat diseases

Website Pipeline 2023.jpg

ANV221 & ANV333 - Targeting the Cancer Glycobiome 
(Not yet FDA/EU approved - for clinical awareness, research, and investor purposes only)

*Oncotarget. 2016; 7:35478-35489. https://doi.org/10.18632/oncotarget.8155

Anviron Sept .jpg
Slide2.JPG
"...Further exploration of the anticancer effects of ANV221, ANV322 in trastuzumab-resistant Her2+ breast cancer is warranted." 
- Yang, Song et al 2023, Journal of Clinical Investigation
bottom of page